Search Results
Aug 04, 2026, 12:37 ET REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Aug 04, 2026, 10:22 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." Following this news, the price of Regeneron's common stock declined even further. From a closing market price of $698.25 per share on May 15, 2026,
More news about: The Gross Law Firm
Aug 04, 2026, 10:00 ET Two Years of Surface Work. Three Priority Targets. Now the Drills Are Permitted in One of the World's Last Undrilled Epithermal Districts.
drill.For investors, Glamorgan permits arrive alongside the Auld Creek project which is entering the Fast Track permitting process and Q4 2026 PFS completion, creating multiple independent catalysts on different timelines. Whether the market has fully appreciated the combination of a potential Fast-Track
More news about: USA News Group
Aug 04, 2026, 09:00 ET Eagle Nuclear Energy Corp. Holds the Rights to the Largest conventional, measured and indicated uranium Deposit in the USA, and It's Systematically Advancing It Toward Development
providing resource and permitting support for the Project, respectively. The PFS itself is targeted for completion in the second half of 2027.Eagle Nuclear's treasury is fully funded through to the completion of the PFS. In its second-quarter 2026 corporate update, Eagle reported approximately US$28
More news about: USA News Group
Aug 04, 2026, 06:00 ET IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
pembrolizumab (anti-PD-1). The primary endpoint is median progression-free survival (PFS) as assessed by blinded independent central review (BICR). Secondary endpoints include safety and investigator assessed PFS, overall response rate (ORR), disease control rate (DCR) and duration of response.
More news about: IDEAYA Biosciences, Inc.
Aug 03, 2026, 07:00 ET Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
and low PTEN H-scores predicted patient response in preclinical studies. These findings were further correlated with longer Progression Free Survival (PFS) in clinical studies, specifically for NSCLC patients with TROP2 H-scores above 100 and PTEN H-scores below 100. This data underscores the potential
More news about: Genprex, Inc.
Aug 03, 2026, 07:00 ET Compugen Reports Second Quarter 2026 Results
observed with COM701 as mono- and combination therapy in heavily pre-treated platinum-resistant patients. The Company believes that clear prolongation of PFS in these patients versus placebo could inform a registration path for COM701 and establish it as a potential backbone for drug combinations. Clinically
More news about: Compugen Ltd.
Aug 03, 2026, 01:58 ET IMPACT Therapeutics unterzeichnet Exklusivlizenzvertrag mit Pharmanovia für Senaparib in Europa, dem Nahen Osten und Nordafrika, Australien und Neuseeland
seit dem 1. Januar 2026 für alle Patientinnen mit Eierstockkrebs in der Erstlinienbehandlung erstattungsfähig. Senaparib erzielte zudem das günstigste PFS-Ergebnis unter den PARP1/2-Inhibitoren (ohne direkten Vergleich) bei der Erstlinien-Erhaltungstherapie für alle Patientinnen mit Eierstockkrebs in China
More news about: IMPACT Therapeutics
Aug 02, 2026, 10:01 ET New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
local trial sites around the country.The primary endpoint of the study is progression-free survival (PFS) by investigator assessment in the FL population, and the key secondary endpoints are PFS in the overall population as well as positron emission tomography complete response (PET-CR) and overall
More news about: Specialised Therapeutics
Jul 31, 2026, 14:32 ET Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint
More news about: Hagens Berman Sobol Shapiro LLP
Jul 31, 2026, 07:47 ET AbbVie Reports Second-Quarter 2026 Financial Results
EPCORE FL-1 trial, in which fixed-duration Tepkinly plus R2 achieved statistically significant improvement of progression-free survival (PFS) and overall response rates (ORR) compared to R2, with approximately three out of four patients achieving a complete response (CR). This approval
More news about: AbbVie
Jul 31, 2026, 04:03 ET IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
"all-comers" in China in January 2025, and is reimbursable for OC 1L "all-comers" since January 1, 2026. Senaparib also delivered the most favorable PFS outcome among PARP1/2 inhibitors (non head-to-head) for 1L maintenance therapy for OC "all-comers" in China, setting a new benchmark in this class.Our
More news about: IMPACT Therapeutics
Jul 31, 2026, 03:48 ET IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
"all-comers" in China in January 2025, and is reimbursable for OC 1L "all-comers" since January 1, 2026. Senaparib also delivered the most favorable PFS outcome among PARP1/2 inhibitors (non head-to-head) for 1L maintenance therapy for OC "all-comers" in China, setting a new benchmark in this class.Our
More news about: IMPACT Therapeutics
Jul 30, 2026, 16:05 ET Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
– The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) –– A Trend Favoring the Selinexor Arm was Observed with a 5.3 Month Improvement in Median PFS Relative to the Placebo Arm in the mITT Population; Company Plans to Continue to Follow
More news about: Karyopharm Therapeutics Inc.
Jul 30, 2026, 10:00 ET New Zealand Just Handed RUA GOLD a Six-Month Permitting Clock: The Drills, the Studies, and the Community are Ready
clock. The substantive application will be submitted later in 2026, supported by the completed PFS. The expert panel has six months to issue its determination. For investors, the key milestones are the PFS completion in Q4 2026, the substantive application submission, the panel determination timeline,
More news about: USA News Group
Jul 30, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)."On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.Pomerantz LLP, with
More news about: Pomerantz LLP
Jul 30, 2026, 07:45 ET Hot Chili Quarterly Report - Period Ending 30 June 2026
and exclusions. The PFS Technical Report is intended to be read as a whole, and sections should not be read or relied upon out of context. The technical information in this report is subject to the assumptions and qualifications to be contained in the PFS Technical Report. The PFS Technical Report replaces
More news about: Hot Chili Limited
Jul 29, 2026, 13:50 ET REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint
More news about: Hagens Berman Sobol Shapiro LLP
Jul 29, 2026, 10:09 ET REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron Pharmaceuticals, Inc. Stockholders of Securities Class Action - Contact the Firm
therapies.Regeneron later disclosed that the PFS analysis would consider all enrolled patients with at least six months of follow-up.The May 15, 2026 announcement stated that the Phase 3 Trial of Fianlimab did not reach statistical significance for improvement in PFS.Plaintiffs contend the protocol
More news about: Levi & Korsinsky, LLP
Jul 28, 2026, 10:10 ET Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Jul 28, 2026, 10:09 ET REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals, Inc. Securities Class Action - Contact The Gross Law Firm
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." Following this news, the price of Regeneron's common stock declined even further. From a closing market price of $698.25 per share on May 15, 2026,
More news about: The Gross Law Firm
Jul 28, 2026, 07:49 ET La Verde Emerging as Hot Chili's Cornerstone Asset
recording a further 200m down-hole of mineralisation across La Verde's western flank.Advancing Toward Maiden MRE and Pre-Feasibility Study (PFS) IntegrationHydrogeological, geotechnical, metallurgical, mine engineering and environmental workstreams are all advancing well toward full
More news about: Hot Chili Limited
Jul 27, 2026, 17:33 ET Regeneron Pharmaceuticals (NASDAQ: REGN) Investors Who Suffered Losses May Be Eligible to Participate in the Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses
survival (PFS) is a clinical-trial endpoint that measures the length of time patients remain alive without their disease worsening or progressing.The complaint alleges that the Fianlimab-Libtayo Phase 3 study failed to achieve statistical significance for its primary PFS endpoint.Who
More news about: Robbins LLP
Jul 27, 2026, 09:30 ET INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Jul 27, 2026, 09:15 ET Everything Went Right for Nuclear This Year. The Stocks Fell Anyway.
about the purpose of the drilling to come, describing it as designed to provide the samples and data that will feed the various studies comprising the PFS.That is narrower language than the exploration sector usually permits itself, and it matters. This is not drilling to find something. The resource
More news about: Equity Insider